Gerpevir – capsules, lyophilisate, suspension, tablets
Inside, intravenously.
To prevent relapses of Herpes simplex, patients with immunodeficiency are prescribed 200 mg 4 times a day every 6 hours. In case of severe immunodeficiency (after bone marrow transplantation or in case of impaired absorption from the intestine) - 400 mg 5 times a day.
Children over 6 years old - 800 mg 4 times a day; 2-6 years - 400 mg 4 times a day; under 2 years - 200 mg 4 times a day. More accurately, the dose can be determined at the rate of 20 mg/kg, but not more than 800 mg 4 times a day. The course of treatment is 5 days.
For children from 3 months to 12 years, the dose for intravenous administration is determined based on body area: infections caused by the Herpes simplex virus - 250 mg/sq.m of body surface every 8 hours; reduced immunity, herpetic encephalitis, chickenpox, herpes zoster - 500 mg/sq.m.
Inside. Genital herpes: initial therapy - 200 mg every 4 hours while awake, 5 times a day for 10 days;
recurrent genital herpes (less than 6 episodes per year), intermittent therapy - 200 mg every 4 hours while awake, 5 times a day for 5 days;
recurrent genital herpes (more than 6 episodes per year), long-term suppressive therapy - 400 mg 2 times a day or 200 mg 3-5 times a day.
Herpes simplex of the skin and mucous membranes (treatment): 200-400 mg 5 times a day for 10 days in patients with impaired immunity.
Herpes simplex of the skin and mucous membranes (prevention): 400 mg every 12 hours.
Herpes zoster: 800 mg every 4 hours while awake, 5 times a day for 7-10 days.
Chicken pox: 800 mg 4 times a day for 5 days. Treatment should begin at the earliest signs or symptoms of chickenpox.
For chronic renal failure, dose adjustment is necessary depending on the size of the CK and the required dosing regimen for normal renal function: normal renal function and chronic renal failure with CK more than 10 ml/min - 200 mg every 4 hours, 5 times a day CK less than 10 ml/min - 200 mg every 12 hours;
normal renal function, chronic renal failure with creatinine clearance more than 10 ml/min - 400 mg every 12 hours, with creatinine clearance less than 10 ml/min - 200 mg every 12 hours;
normal renal function, chronic renal failure with CK more than 25 ml/min - 800 mg every 4 hours while awake, 5 times a day, CK 10-25 ml/min - 800 mg every 8 hours, CK less than 10 ml/min - 800 mg every 12 hours
Children under 2 years of age - the dose has not been determined. However, when studying the drug, no unusual toxic effects or specific pediatric problems were identified in children receiving acyclovir in doses of up to 3 g/m2 and 80 mg/kg per day.
Children 2-12 years old, weighing up to 40 kg, with chickenpox: orally, 20 mg/kg, up to 800 mg per dose, 4 times a day for 5 days.
Children 2-12 years old, weighing 40 kg or more, with chickenpox: adult dose.
IV drip (administered at a constant rate for at least 1 hour).
Severe genital herpes, initial therapy: adults and children over 12 years of age - 5 mg/kg every 8 hours for 5 days; children under 12 years old - 250 mg/sq.m every 8 hours for 5 days.
Herpes simplex of the skin and mucous membranes in patients with impaired immunity: adults and children over 12 years old - 5-10 mg/kg every 8 hours for 7 days; children under 12 years old - 250 mg/sq.m every 8 hours for 7 days.
Encephalitis caused by the Herpes simplex virus: adults and children over 12 years of age - 10 mg/kg every 8 hours for 10 days; children from 3 months to 12 years - 20 mg/kg every 8 hours for 10 days.
Herpes zoster in patients with impaired immunity: adults and children over 12 years of age - 10 mg/kg every 8 hours for 7 days; children under 12 years of age - 20 mg/kg every 8 hours for 7 days.
Generalized infection in newborns caused by the Herpes simplex virus: newborns and children under 3 months - 10 mg/kg every 8 hours for 10 days. A dose of 15-20 mg/kg every 8 hours can be used, but the effectiveness and safety of such doses have not been established.
For chronic renal failure in adults and children, a dose reduction and/or change in the interval between administration is required: CC more than 50 ml/min, dose - 100%, interval - 8 hours; CC 25-50 ml/min, dose - 100%, interval - 12 hours; CC 10-25 ml/min, dose - 100%, interval - 24 hours; CC less than 10 ml/min, dose - 50%, interval - 24 hours.
The maximum dose for adults when administered intravenously is 30 mg/kg or 1.5 g/m2/day.
Gerpevir ointment for external use. approx. 25 mg/g 5 g tube No. 1
Trade name Gerpevir
International nonproprietary name Acyclovir Dosage form Ointment 2.5% Composition: 1 g of ointment contains the active substance - acyclovir in terms of 100% substance 25 mg; excipients: proxanol 268, propylene glycol, polyethylene oxide 400, emulsifier No. 1.
Description Homogeneous ointment of white color with a slight specific odor.
Pharmacotherapeutic group. Antiviral drugs for topical use. Antiviral drugs. ATC code D06B B03
Pharmacological properties Pharmacokinetics When applied externally, it is practically not absorbed into the systemic circulation and does not have a systemic effect. When applying the ointment to the affected area of the skin, a therapeutic concentration of the drug is created in it, which is maintained at a constant level for at least 5 hours. Pharmacodynamics Acyclovir is an analogue of the purine nucleoside deoxyguanidine component of DNA. The drug is especially effective against herpes simplex and herpes zoster viruses. The similarity of the structures of acyclovir and deoxyguanidine allows acyclovir to interact with viral enzymes, which leads to an interruption of the virus reproduction cycle. After penetration of acyclovir into a cell affected by herpes under the influence of thymidine kinase secreted by the virus, acyclovir is converted into acyclovir monophosphate, which is converted into acyclovir diphosphate by host cell enzymes, after which it is converted into the active form acyclovir triphosphate, which selectively blocks the synthesis of viral DNA. Acyclovir triphosphate has virtually no effect on the DNA replication of the host (human) cell. Acyclovir for herpes prevents the formation of new rash elements, reduces the likelihood of skin dissemination and visceral complications, accelerates the formation of crusts, and reduces pain in the acute phase of herpes zoster.
Indications for use Infections of the lips and face caused by the herpes simplex virus (Herpes labialis).
Directions for use and dosage: For external use only! It is recommended to use rubber gloves or finger caps to prevent the spread of infection. Treatment should be prescribed when the first symptoms of a herpes infection occur. For use in adults and children over 12 years of age. The ointment is applied to the affected skin and external mucous membranes. Before applying the ointment, the affected surface must be washed with soap and water and dried thoroughly. The ointment is applied in a thin layer at the rate: a 1.25 cm strip of ointment should be applied to 25 cm2 of the affected area 5 times a day at approximately 4-hour intervals, with the exception of night time. The ointment should also be applied to areas bordering the affected surface. The ointment must be applied regularly; in cases where you miss the next application, you should not double the dose the next time you use the drug. Treatment should continue for at least 4 days. If healing does not occur, treatment can be continued for up to 10 days. If the symptoms of the disease do not disappear after 10 days of treatment, the patient should consult a doctor.
Side effects Allergic reactions: temporary, rapidly passing acute or burning pain, slight drying and flaking of the skin, erythema (redness), itching, rarely rash, in isolated cases, immediate hypersensitivity reactions, including angioedema. If it gets on the internal mucous membranes, inflammation may develop.
Contraindications Hypersensitivity to acyclovir or other components of the drug, as well as to valacyclovir. Infectious diseases with similar symptoms, but caused by other pathogens. Pregnancy, lactation period. Children's age up to 12 years.
Drug interactions The interaction of Gerpevir ointment with other drugs that are also used topically has not been studied.
Special instructions Avoid accidental contact of the ointment with the eyes. Persons with herpes labialis should be warned against contact transmission of the virus to other people, especially in the presence of open lesions. The ointment should only be used to treat herpes on the lips and face. It is not recommended to apply the ointment to the mucous membranes of the mouth, eyes, or use it to treat genital herpes. Persons with particularly severe manifestations of Herpes labialis need to consult a doctor. It is not recommended for use by persons with immunodeficiency. Such patients require consultation with a physician regarding treatment of any infection. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms There are no data on the possible effect.
Overdose Symptoms: erythema, peeling, burning sensation, burn, which disappear soon after discontinuation of the drug. Treatment: drug withdrawal.
Release form and packaging 5 g or 15 g of the drug are placed in an aluminum tube. 1 tube, along with instructions for medical use in the state and Russian languages, is placed in a cardboard pack.
Storage conditions Store in a dry place at a temperature from 8C to 15C. Keep out of the reach of children.
Shelf life: 3 years Do not use after the expiration date indicated on the package! Conditions for dispensing from pharmacies: without a prescription
Gerpevir tablets 400 mg No. 10 Arterium
The tablet should be taken whole with water. When using high doses of acyclovir, an adequate level of hydration should be maintained.
Adults
Treatment of infections caused by the herpes simplex virus.
To treat infections caused by the herpes simplex virus, it is necessary to take Gerpevir tablets at a dose of 200 mg 5 times a day at approximately 4-hour intervals, with the exception of the night period.
Treatment should last 5 days, but in case of severe primary infection it can be continued.
For patients with severe immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced absorption in the intestine, the dose can be doubled to 400 mg or the appropriate dose can be used for intravenous administration.
Treatment should begin as soon as possible after the onset of infection. In the case of recurrent herpes, it is better to start treatment in the prodromal period or after the first signs of skin lesions appear.
Prevention of relapses (suppressive therapy) of infections caused by the herpes simplex virus
. In patients with normal immunity, to prevent relapses of infections caused by the herpes simplex virus, Gerpevir tablets in a dose of 200 mg are taken 4 times a day with a 6-hour interval.
For convenience, most patients can take 400 mg of Gerpevir 2 times a day at 12-hour intervals.
Treatment will be effective even after discontinuation of Gerpevir tablets up to 200 mg, which are taken 3 times a day with an 8-hour interval or even 2 times a day with a 12-hour interval.
In some patients, radical improvement is noted after taking a daily dose of Gerpevir 800 mg.
To monitor possible changes in the natural course of the disease, therapy with Gerpevir should be periodically interrupted at intervals of 6–12 months.
Prevention of infections caused by herpes simplex virus
. To prevent infections caused by the herpes simplex virus, patients with immunodeficiency should take Gerpevir tablets at a dose of 200 mg 4 times a day with a 6-hour interval. For patients with significant immunodeficiency (for example, after bone marrow transplantation) or in patients with reduced absorption in the intestine, the dose can be doubled to 400 mg or the appropriate dose can be used for intravenous administration.
The duration of prophylaxis depends on the length of the risk period.
Treatment of chickenpox and herpes zoster
. To treat infections caused by varicella zoster and herpes zoster viruses, Gerpevir tablets should be taken at a dose of 800 mg 5 times a day at 4-hour intervals, with the exception of the night period. Treatment should continue for 7 days.
For patients with severe immunodeficiency (for example, after bone marrow transplantation) or patients with reduced absorption in the intestine, it is better to use intravenous administration.
Treatment should begin as soon as possible after the onset of the disease; the result will be better if treatment is started immediately after the appearance of the rash.
Elderly patients
. The possibility of renal impairment in elderly patients should be kept in mind, and the dose for them should be adjusted accordingly (see Renal failure). It is necessary to maintain an adequate level of body hydration.
Kidney failure
. Gerpevir should be prescribed with caution to patients with renal failure. It is necessary to maintain an adequate level of body hydration.
When preventing and treating infections caused by the herpes simplex virus in patients with renal failure, recommended oral doses do not lead to the accumulation of acyclovir, the level of which would exceed the safe level established for intravenous administration. However, for patients with severe renal failure (creatinine clearance <10 ml/min), it is recommended to set the dose to 200 mg 2 times a day with an interval of about 12 hours.
For the treatment of infections caused by the Varicella zoster
(chickenpox and herpes zoster), for patients with significantly reduced immunity, it is recommended for severe renal failure (creatinine clearance <10 ml/min) to set a dose of 800 mg 2 times a day at approximately 12-hour intervals, and for patients with moderate renal failure (creatinine clearance within 10–25 ml/min) - 800 mg 3 times a day with an interval of about 8 hours.
Children
. Gerpevir tablets are used in children over 2 years of age.
For the treatment and prevention of infections caused by the herpes simplex virus in children with immunodeficiency over the age of 2 years, doses as for adults can be used.
For the treatment of chickenpox in children aged 6 years and older, 800 mg of Gerpevir 4 times a day; children aged 2–6 years can receive 400 mg of Gerpevir 4 times a day. The duration of treatment is 5 days.
More accurately, the dose can be calculated based on the child’s body weight - 20 mg/kg body weight per day (do not exceed 800 mg) of Gerpevir, divided into 4 doses.
There are no specific data on the use of Gerpevir for the prevention (prevention of relapses) of infections caused by the herpes simplex virus, or for the treatment of infections caused by the herpes zoster virus in children with normal immunity.
This dosage form of the drug is not prescribed to children under 2 years of age.
Gerpevir ointment 2.5% 15g No. 1
Name
Gerpevir ointment d/nar.prim. 2.5% in tubes 15g per pack. No. 1
Description
A homogeneous ointment of white color with a slight specific odor.
Main active ingredient
Acyclovir
Release form
5 g or 15 g per tube, 1 tube per pack.
Dosage
2.5% in tubes 15g per pack. No. 1
Pharmacodynamics
Acyclovir is an antiviral drug. In experimental in vitro studies, it demonstrates activity against the herpes simplex virus types I and II. When it enters cells infected with the herpes virus, acyclovir is phosphorylated and converted into its active form, acyclovir triphosphate. The first step of this process depends on the presence of HSV-encoded thymidine kinase. Acyclovir triphosphate acts as an inhibitor and substrate for herpes-specific DNA polymerase, preventing further synthesis of viral DNA without affecting normal cellular processes.
Pharmacokinetics
When using the ointment in recommended doses, systemic absorption is minimal.
Indications for use
Acyclovir is indicated for the treatment of infections of the lips and face caused by the Herpes simplex virus (recurrent herpes labialis). Use in immunocompromised patients: Use is not recommended in immunocompromised patients and should consult a physician regarding treatment of any infection.
Directions for use and doses
The drug is intended for external use only. For children over 12 years of age and adults, Gerpevir® ointment should be applied 5 times a day at approximately 4-hour intervals, with the exception of night time. It is important to begin treatment as quickly as possible at the onset of infection, preferably during the prodromal period. Treatment should continue for at least 4 days. If healing does not occur, treatment can be continued for up to 10 days. If the symptoms of the disease do not disappear after 10 days of treatment, the patient should consult a doctor. To prevent the condition from worsening and to prevent the transmission of infection, it is necessary to wash your hands before and after applying the drug, and do not rub or touch the affected areas of the skin with a towel.
Interaction with other drugs
Interaction with other drug interactions. No data available.
Contraindications
Hypersensitivity to acyclovir or other components of the drug, as well as to valacyclovir. Special instructions Avoid accidental contact of the ointment with the eyes. Persons with herpes labialis should be warned against contact transmission of the virus to other people, especially in the presence of open lesions. The ointment should only be used to treat herpes on the lips and face. It is not recommended to apply the ointment to the mucous membranes of the mouth, eyes, or use it to treat genital herpes. Persons with particularly severe manifestations of Herpes labialis need to consult a doctor. It is not recommended for use by persons with immunodeficiency. Such patients require consultation with a physician regarding treatment of any infection. This medicine contains propylene glycol, which may cause skin irritation. Use during pregnancy or breastfeeding. For pregnant women and women who are breastfeeding, the drug is recommended to be used only in cases where the benefit, in the opinion of the doctor, outweighs the risk. The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No data available. Use in children. Due to the lack of adequate data, the use of the drug in children under 12 years of age is not recommended.
Compound
active ingredient: 1 g of ointment contains acyclovir in terms of 100% substance 25 mg; excipients: poloxamer*, propylene glycol, polyethylene oxide 400, emulsifier No. 1. * proxanol 268 Dosage form. Ointment for external use. A homogeneous ointment of white color with a slight specific odor.
Overdose
In places where the ointment is applied for a long time, the following are possible: erythema, peeling, burning sensation, burns, which disappear soon after discontinuation of the drug. If you suspect an overdose, you should seek medical help.
Side effect
Adverse reactions are indicated using the following system for classifying adverse effects by frequency: very common? 1/10, often ? 1/100 and
Storage conditions
Store in original packaging at a temperature not exceeding 25 °C. Keep out of the reach of children.
